Background The number of reports of influenza-vaccine-associated Guillain-Barré syndrome to the national Vaccine Adverse Event Reporting System increased from 37 in 1992-1993 to 74 in 1993-1994, arousing concern about a possible increase in vaccine-associated risk.
Methods Patients given a diagnosis of the Guillain-Barré syndrome in the 1992-1993 and 1993-1994 influenza-vaccination seasons were identified in the hospital-discharge data bases of four states.
Vaccination histories were obtained by telephone interviews during 1995-1996 and were confirmed by the vaccine providers.
Disease with an onset within six weeks after vaccination was defined as vaccine-associated.
Vaccine coverage in the population was measured through a random-digit-dialing telephone survey.
Results We interviewed 180 of 273 adults with the Guillain-Barré syndrome ; 15 declined to participate, and the remaining 78 could not be contacted.
The vaccine providers confirmed influenza vaccination in the six weeks before the onset of Guillain-Barré syndrome for 19 patients.
The relative risk of the GuilIain-Barré syndrome associated with vaccination, adjusted for age, sex, and vaccine season, was 1.7 (95 percent confidence interval, 1.0 to 2.8 ; P=0.04).
The adjusted relative risks were 2.0 for the 1992-1993 season (95 percent confidence interval, 1.0 to 4.3) and 1.5 for the 1993-1994 season (95 percent confidence interval, 0.8 to 2.9). (...)
Mots-clés Pascal : Polyradiculonévrite Guillain Barré, Etude longitudinale, Association, Grippe, Virose, Infection, Vaccination, Facteur risque, Etiopathogénie, Questionnaire, Homme, Etats Unis, Amérique du Nord, Amérique, Système nerveux pathologie, Nerf périphérique pathologie, Maladie inflammatoire, Immunoprophylaxie
Mots-clés Pascal anglais : Guillain Barré syndrome, Follow up study, Association, Influenza, Viral disease, Infection, Vaccination, Risk factor, Etiopathogenesis, Questionnaire, Human, United States, North America, America, Nervous system diseases, Peripheral nerve disease, Inflammatory disease, Immunoprophylaxis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0048855
Code Inist : 002B17F. Création : 31/05/1999.